PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

PROCEPT BioRobotics Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$18.28+0.71 (+4.04%)

Close on Oct 19, 2026

Market cap: $1.04B
P/E (TTM): –
Dividend yield: –

PROCEPT BioRobotics Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	308	224	136	75	34	7.72
Cost of Revenue	112	87	65	38	19	8.97
Gross Profit	196	137	71	37	16	-1.26
Research & Development	71	62	48	29	19	16
Selling, General & Admin	229	171	132	89	51	30
Advertising Expenses	0.60	0.50	0.30	0.10	0.10	–
Operating Expenses	300	234	180	118	70	47
Operating Income	-104	-97	-109	-81	-54	-48
Interest Expense	3.59	4.18	4.00	5.18	5.81	5.26
Interest & Investment Income	12	11	7.55	2.50	0.08	0.18
Other Non-Operating Income	-0.16	-1.03	-0.10	-0.20	-0.15	-0.03
Asset Impairment Charges	–	–	–	–	0	0
Pretax Income	-95	-91	-106	–	–	–
Income Tax Expense	0.19	0.37	0.08	0	0	0
Net Income	-96	-91	-106	-87	-60	-53
EPS (Basic)(per share)	-1.72	-1.75	-2.24	-1.96	-3.63	-14.47
EPS (Diluted)(per share)	-1.72	-1.75	-2.24	-1.96	-3.63	-14.47
Shares Outstanding (Basic, Weighted)(shares)	56	52	47	44	16	3.66
Shares Outstanding (Diluted, Weighted)(shares)	56	52	47	44	16	3.66
EBITDA	-97	-91	-105	-78	-51	-45
Provision for Credit Losses	–	0.84	0	0	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.2%
Operating margin: -33.9%
Net margin: -32.5%
Return on equity, FY2025: -24.9%

Financial strength

Current ratio: 6.55
Debt to equity: 0.15
Debt to assets: 10.8%
Cash to current liabilities: 355.0%

Valuation

P/E ratio: –
Price to sales: 3.09
Price to book: 3.07
Dividend yield: –